Updated just now · Live
Stock analysis, price data, and AI-powered insights for Savara Inc (SVRA).
Savara Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for SVRA.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). SVRA Stock Intelligence Report. [stoxpulse.com/stocks/svra]
Disclaimer: The information on this page about Savara Inc (SVRA) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Savara Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Savara Announces New Employment Inducement Grant
4d ago
Savara announces the U.S. Food & Drug Administrati...
6d ago
StoxPulse AI results for SVRA: Pulse Score 49/100. Primary sentiment trends from 4 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$1.15B
P/E Ratio
—
EPS
$-0.14
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Savara Announces New Employment Inducement Grant
Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP)
Savara Announces FDA Extends Review Period For Molgramostim Inhalation Solution Biologics License Application In Autoimmune Pulmonary Alveolar Proteinosis
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference